CA2384499A1 - Sequences de tumeurs ovariennes et procedes d'utilisation correspondants - Google Patents

Sequences de tumeurs ovariennes et procedes d'utilisation correspondants Download PDF

Info

Publication number
CA2384499A1
CA2384499A1 CA002384499A CA2384499A CA2384499A1 CA 2384499 A1 CA2384499 A1 CA 2384499A1 CA 002384499 A CA002384499 A CA 002384499A CA 2384499 A CA2384499 A CA 2384499A CA 2384499 A1 CA2384499 A1 CA 2384499A1
Authority
CA
Canada
Prior art keywords
polypeptide
ovarian carcinoma
polynucleotide
polynucleotides
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002384499A
Other languages
English (en)
Inventor
Jiangchun Xu
John A. Stolk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/640,173 external-priority patent/US6613515B1/en
Application filed by Individual filed Critical Individual
Publication of CA2384499A1 publication Critical patent/CA2384499A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des compositions et des procédés utilisés dans les thérapies et diagnostiques du cancer tel que le cancer de l'ovaire. Ces compositions peuvent comprendre une ou plusieurs protéines du carcinome de l'ovaire, des parties de celles-ci, des polynucléotides codant ces parties ou anticorps ou des cellules du système immun spécifiques de ces protéines. Ces compositions, peuvent être utilisées, par exemple, dans la prévention et le traitement de maladies telles que le cancer de l'ovaire. Des polypeptides et des polynucléotides peuvent être également utilisés dans la détection et la surveillance du cancer de l'ovaire.
CA002384499A 1999-09-10 2000-09-08 Sequences de tumeurs ovariennes et procedes d'utilisation correspondants Abandoned CA2384499A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US39437499A 1999-09-10 1999-09-10
US09/394,374 1999-09-10
US56177800A 2000-05-01 2000-05-01
US09/561,778 2000-05-01
US09/640,173 2000-08-15
US09/640,173 US6613515B1 (en) 1999-09-10 2000-08-15 Ovarian tumor sequences and methods of use therefor
US65666800A 2000-09-07 2000-09-07
US09/656,668 2000-09-07
PCT/US2000/024827 WO2001018046A2 (fr) 1999-09-10 2000-09-08 Sequences de tumeurs ovariennes et procedes d'utilisation correspondants

Publications (1)

Publication Number Publication Date
CA2384499A1 true CA2384499A1 (fr) 2001-03-15

Family

ID=27503365

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384499A Abandoned CA2384499A1 (fr) 1999-09-10 2000-09-08 Sequences de tumeurs ovariennes et procedes d'utilisation correspondants

Country Status (4)

Country Link
EP (1) EP1212354A2 (fr)
AU (1) AU7129700A (fr)
CA (1) CA2384499A1 (fr)
WO (1) WO2001018046A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US20020072503A1 (en) * 2000-03-28 2002-06-13 Jiangchun Xu Compositions and methods for the therapy and diagnosis of ovarian cancer
US6632630B2 (en) 2000-03-29 2003-10-14 Aclara Biosciences, Inc. Monooxygenase assays
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002036624A2 (fr) * 2000-10-30 2002-05-10 Board Of Regents, The University Of Texas System Procedes et compositions associes a la fortiline, une molecule anti-apoptotique, et modulateurs de fortiline
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
WO2003059256A2 (fr) * 2001-12-21 2003-07-24 Idec Pharmaceuticals Corporation Genes surexprimes par le cancer de l'ovaire et leur utilisation dans l'elaboration de nouvelles therapies notamment des anticorps
EP2011886A3 (fr) * 2002-04-16 2009-02-11 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic d'une tumeur
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
WO2004006837A2 (fr) 2002-07-12 2004-01-22 The Johns Hopkins University Vaccins a la mesotheline et systemes de modele
US20090016963A1 (en) * 2003-10-22 2009-01-15 Dalia Cohen Genes involved in neurodegenerative conditions
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0972201T3 (da) * 1997-02-25 2006-01-02 Corixa Corp Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf

Also Published As

Publication number Publication date
WO2001018046A3 (fr) 2001-09-13
WO2001018046A2 (fr) 2001-03-15
EP1212354A2 (fr) 2002-06-12
AU7129700A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
US6710170B2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US7563880B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US6858710B2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US6504010B1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US20020177552A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001072295A2 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
US6509448B2 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US20070292415A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
CA2384499A1 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
US6720146B2 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001077168A2 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
EP1696028A2 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer du sein
US6958361B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US6613515B1 (en) Ovarian tumor sequences and methods of use therefor
US20110150919A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1961819A2 (fr) Composition et procédés pour la thérapie et le diagnostic du cancer des poumons
US20020082207A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
US6617109B1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020076721A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002062203A9 (fr) Compositions et methodes de therapie et de diagnostic du cancer du sein
WO2001098339A2 (fr) Compositions et procedes de traitement et de diagnostic du cancer du sein
WO2002024057A2 (fr) Compositions et procedes destines a la therapie et au diagnostic du cancer des poumons
EP1268797A2 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
ZA200209365B (en) Compositions and methods for the therapy and diagnosis of breast cancer.

Legal Events

Date Code Title Description
FZDC Discontinued application reinstated
FZDE Discontinued